Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 28;14(13):3167.
doi: 10.3390/cancers14133167.

Immunological Landscape of HER-2 Positive Breast Cancer

Santiago Moragon  1 , Cristina Hernando  1 , Maria Teresa Martinez-Martinez  1 , Marta Tapia  1 , Belen Ortega-Morillo  1 , Ana Lluch  1   2 , Begoña Bermejo  1   2 , Juan Miguel Cejalvo  1   2
Affiliations
Review

Immunological Landscape of HER-2 Positive Breast Cancer

Santiago Moragon et al. Cancers (Basel). .

Abstract

Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.

Keywords: HER2+ breast cancer; PD-L1; anti-HER2 vaccines; immune checkpoint blockade; tumour-infiltrating lymphocytes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Scheme of tumour microenvironment.
Figure 2
Figure 2
Different vaccination models harbouring HER2+ tumours. APC: Antigen-presenting cell.
See this image and copyright information in PMC

References

    1. Modi S., Saura C., Yamashita T., Park Y.H., Kim S.-B., Tamura K., Andre F., Iwata H., Ito Y., Tsurutani J., et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N. Engl. J. Med. 2020;382:610–621. doi: 10.1056/NEJMoa1914510. - DOI - PMC - PubMed
    1. Diéras V., Miles D., Verma S., Pegram M., Welslau M., Baselga J., Krop I.E., Blackwell K., Hoersch S., Xu J., et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732–742. doi: 10.1016/S1470-2045(17)30312-1. - DOI - PMC - PubMed
    1. Datta J., Rosemblit C., Berk E., Showalter L., Namjoshi P., Mick R., Lee K.P., Brod A.M., Yang R.L., Kelz R.R., et al. Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. OncoImmunology. 2015;4:e1022301. doi: 10.1080/2162402X.2015.1022301. - DOI - PMC - PubMed
    1. Soberino J., Racca F., Pérez-García J., García-Fernández L.F., Cortés J. Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. [(accessed on 17 February 2022)];Curr. Breast Cancer Rep. 2019 11:248–258. doi: 10.1007/s12609-019-00332-4. Available online: https://www.researchgate.net/publication/337232152_Immunotherapy_for_HER.... - DOI
    1. Chew V., Toh H.C., Abastado J.-P. Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy. J. Oncol. 2012;2012:608406. doi: 10.1155/2012/608406. - DOI - PMC - PubMed